Crestor achieves results in tackling elevated LDL-C in patients with metabolic syndrome

March 09, 2004

Blood pressure>130/>85mmHgFasting glucose³110mg/dL (6.11mmol/L)
Alone, each risk factor conveys increased cardiovascular disease risk, but in combination they enhance the patient's risk.10 Presence of the metabolic syndrome significantly increases the risk of heart attack, type 2 diabetes and death.2,4

Non-HDL-C
Non-HDL-C is calculated routinely as the amount of total cholesterol (TC) minus the amount of HDL-C. Therefore, non-HDL-C is important as it refers to all the atherogenic lipoproteins fractions.11 High levels of these are an important factor in the development of atherosclerosis.

Cardiovascular Disease
The term cardiovascular disease (CVD) refers to a wide range of disorders affecting the heart and blood vessels. CVD can be sub-divided into the following diseases:
  • coronary heart disease (CHD) (e.g. heart attacks and angina)
  • cerebrovascular disease (e.g. strokes and transient ischaemic attacks)
  • peripheral vascular disease (e.g intermittent claudication)

    CVD is estimated to account for approximately a third of all deaths globally and is the leading cause of mortality in Europe and the US. Over 16.7 million deaths each year are due to CVD (more than 45,000 deaths every day, and almost 32 deaths each minute).12 In Europe, about half of all deaths from CVD are from CHD and nearly one-third are from stroke.13

    For more information please refer to the media backgrounders, 'The metabolic syndrome', 'STELLAR study', 'GALAXY Programme' and 'GALAXY Programme studies', which can be found on: www.AstraZenecaPressOffice.com

    Additional data at ACC
    AstraZeneca will be presenting important new data for EXANTA and ATACAND during the ACC 2004:
  • EXANTA SPORTIF III and V Studies, Monday 8 March, 16.00 - 17.30, Oral Presentation, MCC Convention Center, Room 265: B Olsson, Efficacy and Safety of Ximelagatran Compared with Well-Controlled Warfarin in Elderly Patients with Nonvalvular Atrial Fibrillation: Observations from the SPORTIF Trials. J Halperin, Efficacy and Safety of Ximelagatran Compared with Well-Controlled Warfarin in Women and Men with Nonvalvular Atrial Fibrillation in the SPORTIF Trials: 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, USA, March 2004.
  • ATACAND CHARM Study, Monday 8 March, Morning Session, Poster Session, MCC Convention Center: Scott Solomon et al., Cause of Death Across Full Spectrum of Ventricular Function in Patients with Heart Failure: The CHARM Study: 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, USA, March 2004.
  • Monday 8 March, 11.00 - 12.15, Oral Presentation, Session Number 810, MCC Convention Center: Salim Yusuf et al., Impact of the Angiotensin-Receptor Blocker Candesartan in Preventing Diabetes in Patients With Heart Failure: 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, USA, March 2004.
  • Monday 8 March, 15.00 - 17.00, Poster Session, Session Number 1108, MCC Convention Center: John McMurray et al., Low Hemoglobin is an Independent Predictor of Adverse Fatal and Non Fatal outcomes in Both Reduced and Preserved Systolic Function Chronic Heart Failure: findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity Programme (CHARM): 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, USA, March 2004.
  • Tuesday 9 March, 08.30 - 10.00, Oral Presentation, Session Number 835, MCC Convention Center: John McMurray et al., Candesartan Improves Functional Class Across a Broad Spectrum of Patients With Chronic Heart Failure: Results of the Candesartan in Heart Failure- Assessment of Reduction in Mortality and Morbidity Programme (CHARM): 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, USA, March 2004.
  • Tuesday 9 March, 12.00 - 14.00, Poster Session, Session Number 1145, MCC Convention Center: Karl Swedberg et al., Prevention of AF in Symptomatic Chronic Heart Failure by Candesartan - Results From CHARM: 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, USA, March 2004.

    New CRESTOR data at the European Atherosclerosis Society Congress
    New CRESTOR data looking at its effect on patients with type 2 diabetes will be presented at the European Atherosclerosis Society Congress in Seville, from 17-20 April 2004. For more information about AstraZeneca media activities at this congress please contact: Ellie Goss on 44-207-471-1519 or email ellie.goss@shirehealthinternational.com.

    References:

    1. Deedwania P & Hunninghake D. Comparative Effects of Statins on Atherogenic Dyslipidemia in Patients With the Metabolic Syndrome. 53rd American College of Cardiology (ACC) Congress in New Orleans, USA, March 2004

    2. Isomaa B, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9

    3. Ford ES, et al. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Journal of the American Medical Association 2002;287:356-9

    4. Meigs JB. Epidemiology of the metabolic syndrome. American Journal of Managed Care 2002;8:S282-92

    5. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497. Also available on-line: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm

    6. de Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 2003;24:1601-10

    7. Jones P, Davidson M, Stein E et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses. American Journal of Cardiology 2003;92:152-160

    8. Stender S, Schuster H, Barter P et al. Comparing the Effects of Statins on Cholesterol Goal Achievement and Plasma Lipids in Hypercholesterolaemic Patients with and those without the Metabolic Syndrome: Results from the MERCURY I Trial. Diabetes Metab 2003;29 (Suppl):4S138 Abstract 1833

    9. Stalenhoef AFH, Ballantyne CM, Sarti C et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: rationale and design of the COMETS study. Diabetes Metab 2003;29(Suppl):4S318 Abstract 2559

    10. Kaplan NM. The deadly quartet: upper body adiposity, glucose intolerance, hypertrigylceridaemia and hypertension. Archives of Internal Medicine 1989;149:1514-20

    11. Cui Y, et al. Non-high-density lipoprotein cholesterol level predictor of cardiovascular disease mortality. Archives of Internal Medicine 2001;161:1413-9

    12. World Health Report 2003. World Health Organization. http://www.who.int.

    13. European Cardiovascular Disease Statistics, 2000 Edition, British Heart Foundation. http://www.bhf.org.uk

    Shire Health International

    Related Diabetes Articles from Brightsurf:

    New diabetes medication reduced heart event risk in those with diabetes and kidney disease
    Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

    Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
    Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

    Making sense of diabetes
    Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

    Helping teens with type 1 diabetes improve diabetes control with MyDiaText
    Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

    Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
    Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

    Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
    Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

    Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
    Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

    Maternal gestational diabetes linked to diabetes in children
    Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

    Two diabetes medications don't slow progression of type 2 diabetes in youth
    In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

    People with diabetes visit the dentist less frequently despite link between diabetes, oral health
    Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

    Read More: Diabetes News and Diabetes Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.